Background: Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria. Evidence is lacking in patients with chronic inducible urticarias (CIndUs), which are frequently H 1 -antihistamine resistant. Objective: From the current published literature, we aimed to determine the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs.
Abbreviations used
AE: Adverse event CIndU: Chronic inducible urticaria CSU: Chronic spontaneous urticaria CU: Chronic urticaria DLQI: Dermatology Life Quality Index QoL: Quality of life However, many patients do not, 1, 4 in which case third-line treatments, including omalizumab, are recommended. 1 Omalizumab, a recombinant humanized anti-IgE antibody, is now approved as add-on therapy in patients with H 1 -antihistaminerefractory CSU, and thus from clinical experience, it might be expected that patients with CIndUs could also benefit. 9 Omalizumab has been used to successfully treat CSU, with strong evidence coming from randomized controlled trials, [10] [11] [12] [13] [14] [15] [16] real-life studies, 17 and a meta-analysis. 18 However, omalizumab is not licensed for CIndUs, and large-scale trials are lacking. The first reported case of omalizumab use in a patient with a CIndU was by Boyce 19 in 2006, and since that time, a body of evidence has accumulated in the form of trials, case studies, reports, and retrospective analyses. Some research groups have recommended omalizumab to treat patients with CIndUs who cannot achieve adequate symptom control with conventional therapies. [20] [21] [22] Guideline recommendations for CSU are frequently adopted in the absence of good-quality evidence for CIndUs.
In the current systematic review we have aimed to determine, from the current published literature, existing evidence for the efficacy and safety of omalizumab in the treatment of CIndUs. Some rare atypical forms of CIndUs exist (ie, cholinergic dermographism), but this review focuses on the 9 major subtypes ( Table I) .
The exact pathology of CIndU is yet to be fully elucidated, but the activation and degranulation of tissue-resident mast cells and the subsequent release of inflammatory mediators, such as histamine, play key roles. [23] [24] [25] As of now, it is unclear exactly what causes this activation and degranulation. Type I autoimmunity, sometimes also referred to as autoallergy, has been postulated to be a cause of CIndU. 26 In patients with autoimmune type I urticaria, skin mast cells are activated by an IgEmediated reaction to autoantigen. In patients with CIndUs, the appropriate trigger may result in de novo synthesized autoantigen (autoallergen), which is detected by IgE bound to skin mast cells, resulting in mast cell degranulation (Fig 1) ; this is supported by several independent lines of evidence. [26] [27] [28] Many patients with CSU exhibit IgE autoantibodies directed against thyroid peroxidase (IgE-anti-thyroid peroxidase), and these patients have higher levels of total IgE and IgG-anti-thyroid peroxidase and lymphocyte counts in their serum/blood. 29 Some CIndUs, such as symptomatic dermographism, solar urticaria, and cold urticaria, are transferable, with the transferable serum factor suggested to be IgE. [30] [31] [32] [33] Relevant autoantigens detected by using IgE have been identified and characterized in part, such as in solar urticaria. 34 Desensitization, which works in patients with cold urticaria and other CindUs, has been shown not to work through depletion of mast cells or mast cell mediators, but rather, it is suggested to work through depletion of the mast cell-activating signal. 27 Skin mast cell degranulation in patients with solar urticaria, for example, occurs when skin is exposed to UV radiation. Mast cell degranulation is thought to involve IgE that is specific for photo-induced neoantigens that act as autoallergens. This IgE is bound to FcεRI, the high-affinity IgE receptor on cutaneous mast cells, which is activated by neoantigen-mediated cross-linking of IgE and the receptor. Because omalizumab blocks binding of IgE to FcεRI, 35 it can intervene in this pathway, and mast cell activation and the inflammatory process are suppressed subsequently.
METHODS
We performed a MEDLINE search (pubmed.com) to identify evidence of the use of omalizumab in each CIndU subtype, with no restrictions on time period covered or publication language. The advanced search option was used with the terms ''omalizumab'' AND, for example, ''cold urticaria'' to encompass results from all fields. This was complemented by any additional published or in press evidence known to us at the time of publication (Table II) . 19, 20, All publications have been included, regardless of whether the results were positive or negative, to present a fair and unbiased account of the available published evidence. Review articles have been excluded. Publications have been split into 2 groups based on the number of patients included in the report: case series or studies with 5 or more patients and case reports or small case series of fewer than 5 patients.
RESULTS
We found overlap of CIndU subtypes between studies, and although many of the case studies presented include several patients, the numbers shown in Table II relate only to the number of patients within the specified subtype.
A total of 43 trials, case studies, case reports, and retrospective analyses on the use of omalizumab in patients with CIndUs were identified and included in this review (Fig 2) . Overall, 3 phase II studies were identified in patients with solar urticaria, 36 cold urticaria, 37 and symptomatic dermographism, 38 of which the latter 2 were randomized and placebo controlled. Most published evidence comes from single case reports, small case studies, or larger case studies that also include some patients with CSU.
Overall, the vast majority of results indicate a beneficial role for omalizumab in each type of CIndU, but evidence for certain subtypes was stronger than for others, as described under each heading below. To our knowledge, all doses of omalizumab were administered subcutaneously, as per the instructions. Adverse events (AEs) were generally found to be low, with omalizumab being well tolerated by most patients.
Physical urticarias
Symptomatic dermographism. Symptomatic dermographism is the most common type of physical urticaria, 77 with a prevalence of up to 5% in the general population. 78 It involves whealing and pruritus after minor stroking, rubbing, or scratching of the skin, which can be unavoidable in daily life and can therefore substantially impair QoL. 79, 80 Antihistamines can be used to effectively treat the majority of patients, but in some cases, further treatment is required.
We identified 7 publications on omalizumab use in patients with symptomatic dermographism encompassing a total of 72 patients (including 54 omalizumab-and 18 placebo-treated patients). The strongest evidence came from a randomized, placebo-controlled trial involving 55 patients with symptomatic dermographism, who had a high mean baseline Dermatology Life Quality Index (DLQI) score of 11.1, indicating a very high effect on QoL. 38 Results showed significant improvement in critical friction thresholds (the strongest trigger strength to induce symptoms) after 10 weeks of treatment with 150 mg (21.8 6 0.4, P 5 .014) and 300 mg (22.0 6 0.4, P 5 .004) of omalizumab versus placebo-treated patients (20.6 6 0.3), with improvements observed as early as week 4. No significant difference in efficacy was observed between the 2 omalizumab doses, and efficacy was not affected by variations in baseline trigger thresholds or disease activity. After 10 weeks of treatment, 6 (33%) of 18 receiving 150 mg of omalizumab and 8 (42%) of 19 patients receiving 300 mg of omalizumab did not respond at all compared with 15 (83%) of 18 placebo-treated patients. 38 A retrospective analysis showed 86% of patients achieved a complete response (absence of wheals after provocation testing/ absence of symptoms assessed by Patient Global Assessment) and 14% had a significant improvement (> _50% reduction in provocation thresholds/> _50% improvement of symptoms). 39 Another analysis showed that 1 of 2 patients achieved complete/almost complete response to treatment, 40 and 2 further analyses by Metz et al 41, 42 showed slightly differing results. In the first, one patient who received 300 mg of omalizumab achieved complete symptom control, but another patient, who began treatment with 150 mg and then updosed to 300 mg, did not. 41 Both patients had previously tried 9 different medications to control their CIndU with little success. In the second analysis all 4 patients (1 with symptomatic dermographism plus CSU) gained complete symptom control, with no need for additional medication after the first treatment. 42 Finally, 2 case reports showed further positive results. In the first report a patient with antihistamine-refractory symptomatic dermographism who was treated with 300 mg of omalizumab every 2 weeks gained major reductions in pruritus and whealing within the first week, with complete symptom relief by the fourth week. 43 In the other report a patient with coexisting symptomatic dermographism, delayed-pressure urticaria, and CSU achieved complete remission within 24 hours of receiving 150 mg of omalizumab. 44 Cold urticaria. Cold urticaria is the second most prevalent physical urticaria. 77 Wheals, angioedema, or both develop within minutes of touching something cold, and there is a serious risk of anaphylaxis or oropharyngeal edema. 45, [81] [82] [83] [84] Robust evidence exists for cold urticaria, totaling 63 reported cases of omalizumab use (including 51 omalizumab-and 12 placebo-treated patients) across 11 publications. The first reported use was in 2006 in a 12-year-old patient with a 2-year history of cold urticaria and asthma. 19 The patient was given 375 mg of omalizumab every 2 weeks and, after the second injection, could tolerate cold liquids with only mild pruritus. After 5 months, symptoms had completely disappeared, and ice cube test responses were negative. Encouraging results from this case have been reinforced by a number of subsequent case reports. 41, 42, 45 More recently, results from a randomized, placebo-controlled trial including 31 patients with cold urticaria demonstrated significant clinical superiority of omalizumab versus placebo. 37 Because cold urticaria can be life-threatening, and very limited/ no efficacy was seen with placebo treatment, the study was terminated after interim result analysis. Mean changes in critical temperature thresholds (required to induce symptoms) after 10 weeks were significantly higher in patients receiving 150 mg (210.68C 6 2.48C, P 5 .001) and 300 mg (210.48C 6 3.18C, P 5 .013) of omalizumab compared with placebo (20.38C 6 1.18C). Improvements were seen by week 4. No significant difference in efficacy was observed between the 2 doses, and variations in baseline critical temperature thresholds did not affect efficacy. After 10 weeks of treatment, 1 (10%) of 10 patients receiving 150 mg of omalizumab and 2 (22%) of 9 patients receiving 300 mg of omalizumab were nonresponders compared with 9 (75%) of 12 placebo-treated patients.
Some case series also demonstrate substantial benefits; Kitsioulis et al 46 reported significant QoL improvements in 5 children with cold urticaria (children's DLQI scores decreased by 41.46% [13.4% to 65.3%, SD 5 18.66%]) after 5 months of treatment, whereas an improvement was observed after the first month (decrease range, 17.65% to 40%; SD 5 10.35) in 80% of these patients. Another set of cases showed that 6 patients all became symptom free after treatment, with a significant decrease in cold stimulation tolerance tests. 47 One case report showed significant improvements after an initial omalizumab injection and complete control after the second injection, 48 whereas another described a 2-year-old patient with severe systemic reactions on exposure to cold conditions whose symptoms dramatically improved after treatment with 75 mg of omalizumab every 4 weeks. 49 However, 2 more reports suggest that only around half of patients included in an analyses responded well to omalizumab, 39, 40 and one case described a patient in which 300 mg of omalizumab treatment every 4 weeks did not adequately control symptoms, with treatment discontinued after 8 months because of repeated fatigue and somnolence. 45 Delayed-pressure urticaria. Delayed-pressure urticaria frequently coexists with CSU but is rare as a primary inducible urticaria.
14 Because of its nature, the condition frequently goes unrecognized and can be difficult to attribute to a single trigger because symptoms typically occur 4 to 6 hours after, for example, wearing tight clothing, walking, or sitting. 85 Lesions are painful and persist for up to 3 days. This subtype has been reported to cause significantly greater QoL impairment than other forms of urticaria 86 and is normally unresponsive to high doses of antihistamines or corticosteroids. 50 We identified 11 publications of omalizumab including 26 patients with delayed-pressure urticaria. The first reported use of omalizumab was by Bindslev-Jensen and Skov 51 in a patient with a 10-year history whose previous medications (540 mg/d fexofenadine and 100 mg/d azathioprine) provided only partial relief, the benefits of which were gradually diminishing. Once 150 mg of omalizumab was started (given concomitantly with fexofenadine), total symptom relief was achieved after 2 days. This was followed quickly by more case reports describing complete responders after just 1 injection. 41, 52, 53 In another case involving a patient with coexisting delayed-pressure urticaria, symptomatic dermographism, and CSU, complete remission was seen within 24 hours of 150 mg of omalizumab treatment, 44 and 3 other cases reported the same result in which a 300-mg dose achieved complete symptom control within 2 days 54, 55 and another within 5 days. 50 However, some reports showed mixed results: 2 patients with concurrent CSU and delayed-pressure urticaria showed a complete remission after the first injection of omalizumab. 56 In a third patient with severe delayed-pressure urticaria and CSU who had received ineffectual treatment for more than 20 years, omalizumab reduced the symptoms of CSU but intensified those of delayed-pressure urticaria, and the drug was withdrawn after 2 cycles. In the largest analysis including 8 patients, 7 (88%) achieved complete symptom control, whereas 1 (12%) had significant improvements after treatment, 39 and another showed 3 (60%) of 5 patients with a complete response. 40 Solar urticaria. Solar urticaria is a rare form of CIndU. 87 It is characterized by skin lesions at sites of photo-exposed skin, usually within minutes of UV radiation, including long-wavelength UVA, short-wavelength UVB, and/or visible light. 88 It seriously affects QoL, and there is a risk of anaphylaxis should the entire body be exposed. 87, 89 Of all CIndU subtypes, solar urticaria had the highest number of publications on omalizumab use. Of 18 publications that included 36 cases, the majority showed that omalizumab successfully controlled symptoms, whereas 4 included patients with a partial response, 39, 42, 57, 58 and 3 showed failure to respond to treatment. 40, 59, 60 The strongest evidence came from a multicenter, prospective, phase II study including 10 antihistamine-refractory patients with solar urticaria that greatly affected their QoL (DLQI score of >10). 36 After 3 doses of omalizumab over an 8-week period, 20% of patients met the primary end point (95% CI, 2.52-55.6; P 5 .2639), whereby symptoms were not triggered by a UV dose of greater than 10-fold the baseline minimal urticarial dose at week 12. Additionally, 40% of patients achieved a DLQI score of less than 6, and 40% achieved an improvement in severity (measured on a visual analogue scale) of 50%. No significant AEs were experienced during the study.
Several case reports describe full remission of solar urticaria. 39, 41, 42, [61] [62] [63] [64] [65] [66] [67] Initial doses in these cases ranged from 150 to 375 mg, although in some patients a higher dose of 450 mg was necessary to achieve complete symptom control. 62, 68 Patients often relapsed 2 to 8 weeks after discontinuing treatment but then responded well to the next omalizumab injection. 42 One case of omalizumab use in a 6-year-old child was reported after approval from an ethics committee for exceptional medical treatments. 69 An initial dose of 75 mg did not achieve any apparent improvement, and therefore the dose was gradually increased to 300 mg twice monthly, after which complete remission was gained with no side effects.
In the case of treatment failure, 1 patient received 4 doses of 150 mg of omalizumab every 4 weeks with no clinical improvement and no changes in phototests, although the authors speculate that a higher dose and longer treatment could have been more effective. 59 There was one report of worsening symptoms after 3 doses of 150 mg of omalizumab, indicating that this treatment is not suitable in all patients. 60 Heat urticaria. Heat urticaria is triggered by various forms of heat, such as air, water, or objects. It is an uncommon physical urticaria and difficult to manage effectively. 90 Avoiding all forms of heat poses a great challenge in everyday life and is often not feasible.
Evidence of omalizumab use in patients with heat urticaria is limited and comes from just 4 publications covering 5 case reports. Two patients seriously affected by their condition whose symptoms were insufficiently controlled by conventional treatments achieved marked clinical improvements after the first doses of 300 mg of omalizumab. 70 In one of these cases, the heat application test response became negative.
In another case report, almost complete symptom control was achieved after a patient received 4 doses of omalizumab, alternating between 300 mg and 450 mg biweekly. 20 The 450-mg dose achieved greater symptom improvement compared with the 300-mg dose, and the patient received a total of 38 doses with no side effects and no need for concomitant medication. Two other case reports described less favorable responses with either no significant improvement 39 or only minor improvements in 1 patient with an extremely treatment-resistant form of heat urticaria, as indicated by 9 prior medications, including loratadine, cetirizine, and montelukast. 41 Vibratory angioedema. Vibratory angioedema, a very rare form of CIndU, is characterized by eruption of pruriginous erythema within minutes of vibratory contact to the skin. 4 It is induced typically by vibratory motions, such as running or using an electric lawnmower or pneumatic drill. Only one case report of omalizumab use in vibratory angioedema was found, which did not improve symptoms. 71 Other inducible urticarias Cholinergic urticaria. Cholinergic urticaria is characterized by pin-sized wheals with surrounding erythema and extreme pruritus. Symptoms are induced by increases in core body temperature through, for example, physical exercise or emotional stress. In most cases, symptoms are mild to moderate, but sometimes wheals cover the entire body, and antihistamines are often ineffectual. 91 One case series involving 8 patients 39 and 6 smaller case reports/series 40, 42, [72] [73] [74] [75] were identified for omalizumab use in patients with cholinergic urticaria, totaling 20 reported cases. The retrospective analysis by Metz et al 39 showed that 62% of patients achieved a complete response (absence of wheals after provocation testing/absence of symptoms assessed by Patient Global Assessment), 13% had a significant improvement (> _50% reduction in provocation thresholds/> _50% improvement of symptoms), and 25% showed no significant improvement (<50% reduction in provocation thresholds/improvement of symptoms). Most patients started on 150 mg of omalizumab, with 1 patient receiving 300 mg. Another analysis showed greater benefits: 3 patients with cholinergic urticaria and 1 with cholinergic urticaria plus cold urticaria achieved complete symptom control with no need for any concomitant medication. 42 Disease relapsed within 2 to 8 weeks of omalizumab discontinuation, despite patients taking antihistamines. In another study 75% of patients achieved complete responses with omalizumab therapy. 40 Three case studies indicated great improvement of symptoms: 2 cases describe patients' symptoms drastically improving after only 1 dose of omalizumab, as measured by the DLQI score and the Chronic Urticaria Quality of Life Questionnaire, respectively. 73, 75 In addition, 1 patient had also had severe dyspeptic complaints, which almost completely disappeared. 75 In another case a patient significantly improved after the second injection of 300 mg of omalizumab, and concomitant medication was reduced. 72 One case is reported of a patient whose symptoms were unresponsive to 300 mg of omalizumab treatment given every 2 weeks, although the author speculates that lack of response might be related to high IgE levels, and a higher dose might have produced more successful results. 74 Contact urticaria. Contact urticaria is characterized by wheals and angioedema that occur in response to contact with urticariaogenic substances. Mast cell activation is either nonimmunologic (ie, without prior sensitization to the eliciting agent) or immunologic (ie, IgE mediated). 92 We did not identify any reported uses of omalizumab in patients with contact urticaria.
Aquagenic urticaria. Aquagenic urticaria is a rare inducible CIndU that occurs when the skin is exposed to water, including sweat and tears. Patients typically present with 1-to 3-mm wheals with surrounding 1-to 3-cm erythematous flares within minutes of water contact. 90 In some cases symptoms can be more severe and include wheezing or shortness of breath. The nature of this subtype has an obvious effect on QoL because simple activities, such as bathing, can become almost impossible. Many patients are refractory to H 1 -antihistamines and require further interventions.
Only one case of omalizumab treatment in a patient with aquagenic urticaria was identified. 76 A patient with a 2-year history of aquagenic urticaria whose condition was uncontrolled by previous medications, including montelukast, cetirizine, loratadine, ranitidine, diphenhydramine, and hydroxyzine, was started on 300 mg of omalizumab per month. Symptoms completely resolved after 2 omalizumab doses, and the patients was able to go swimming for the first time in many years and discontinued other medications without symptom recurrence.
AEs
Overall, instances of AEs were low and rarely led to treatment discontinuation. In one study involving a mixture of patients with CSU and those with CIndUs, 14% of patients overall reported AEs during treatment, including suspected allergic reactions, gastrointestinal symptoms, injection-site reactions, worsening urticaria, headache, dizziness, arthritis, and fatigue. 40 In another analysis of 51 patients (again including both patients with CSU and those with CIndU), no unwanted side effects were reported from omalizumab, except one case in which treatment was discontinued after mild cutaneous angioedema several hours after administration. 39 In the 2 placebo-controlled randomized trials in patients with cold urticaria and symptomatic dermographism, the frequency of AEs was similar between the omalizumab and placebo groups. 37 One patient with cold urticaria discontinued treatment because of inadequate symptom control and AEs, including fatigue and somnolence. 45 An investigator-initiated urticaria registry has been set up to prospectively monitor patients with CU (http://www.urticariaregistry.com). This has now almost reached its 1000th patient and will provide valuable future data on the efficacy and AEs of treatments of CIndU patients.
DISCUSSION
A large body of evidence has accumulated for omalizumab use in patients with CIndUs since the first reported use in 2006. 19 Two randomized controlled trials, several sizable case series, and many case reports exist to indicate that omalizumab provides substantial benefits in patients with various CIndUs, but more data on efficacy and safety from controlled (licensing) studies are needed.
The dose of omalizumab used appears to be important based on individual patient needs; because of the nature of this review, which includes all published evidence (excluding review articles), a range of different doses was used across the studies. Some studies showed no apparent difference between omalizumab doses, 37, 38 whereas in many studies a lower dose of 150 mg was sufficient to elicit a good response, 37, 38, 44, 51 and in others higher doses generally appeared to be more efficacious, which is supported by previous evidence. 18 Depending on the type of CIndU and the age and weight of the patient, doses should be tailored to individual patients' needs. In some of the reported treatment failures, it was speculated that a higher dose could have produced more success, and in some cases the benefits of updosing to reach maximal effects were apparent. 62, 68 Differences between omalizumab treatment in patients with CIndU versus patients with CSU were discovered, with the dose required to gain a response being the major difference between the 2 populations. Most randomized trials in patients with CSU have involved omalizumab doses of between 75 and 600 mg, with the majority of patients treated with a 300-mg dose. [10] [11] [12] [13] [14] [15] [16] The effective dose in patients with CSU appears to plateau at around 300 mg, with 75 mg having failed to show a meaningful response, and doses of greater than 300 mg generally not showing greater efficacy in omalizumab-naive patients. However, this differed in responses to omalizumab in patients with CIndUs. The 2 randomized trials in symptomatic dermographism 38 and cold urticaria 37 both tested 150 and 300 mg in the relevant patients, but no significant differences between the doses were observed at any time during the study, indicating that the lower dose of 150 mg might be more appropriate in this patient population. This requires further investigation, including studies that confirm earlier results showing that omalizumab updosing is effective in patients with CIndU (and patients with CSU) who do not respond to their initial dose of omalizumab. 39 One common theme identified was that many patients had already tried several medications in an attempt to control their urticaria symptoms, and for some, most treatment options had been exhausted. Considering this, omalizumab provided at least partial, if not complete, relief for the majority of these patients after several years of discomfort.
Published clinical trials demonstrate that response to omalizumab in patients with CSU is evident within the first weeks of treatment, 10, 13 and our review also supports the rapid onset of action in patients with CIndUs, as demonstrated through early symptom control recorded in most publications. However, the question of time to response is important, and not all patients respond to treatment in the same manner and at the same speed. Time to response has been shown to differ between patients, and future characterization of predictive factors might lead to better prognosis and treatment of distinct patient groups. 93 A recent study in patients with CSU has shown that the majority of patients respond within the first 8 days, with around one third responding on day 1 93 and around 12% not responding. Similar studies are needed for patients with CIndUs.
One publication was identified in which patients received more than 1 course of omalizumab treatment. 42 A total of 16 patients with 5 different CIndUs (some with coexisting CSU) were treated with omalizumab doses of between 150 and 600 mg/mo, and disease activity was determined by trigger threshold testing or by the patient's history. All patients achieved complete symptom control (> _90% improvement) during the first course of treatment. Once discontinued, all patients experienced a relapse of disease, despite antihistamine treatment, within 2 to 8 weeks after their last omalizumab injection (except for 2 patients who relapsed after 4 and 7 months). Retreatment was started at the same dose and regimen of omalizumab as the last successful treatment before discontinuation. On the first reinjection of omalizumab, all patients responded completely and rapidly within 4 weeks but, more commonly, during the first days of retreatment. This was the only publication to specifically investigate relapse of CIndUs and how these patients responded to omalizumab on reinitiation. Interestingly, no patients in this study reported AEs other than mild injection-site reactions during either the initial use or during retreatment.
Variation of omalizumab use was seen between the CIndU subtypes, with the most thorough evidence available in patients with cold urticaria (complete/partial response in 41/51 patients), symptomatic dermographism (complete/partial response in 38/54 patients), and solar urticaria (complete/partial response in 28/36 patients), with the level of complete responders observed in patients with cold urticaria comparable with the efficacy reported from clinical trials with CSU. 94 Little or no evidence was available on vibratory angioedema and aquagenic and contact urticaria, and therefore the use of omalizumab and its outcome in patients with these CIndUs should be documented and reported.
Several cases were identified of omalizumab use in children, 46 ,53,69 and 1 case was identified in a pregnant woman, with no unexpected side effects and no complications or harm to the unborn child. 44 We acknowledge that omalizumab is a costly treatment option compared with some alternative treatments. As yet, no health economic data exist to compare its cost with the health, psychologic, and economic burden of working days lost because of CIndUs.
Other drugs that target IgE are in development, such as the IgG 1 mAbs ligelizumab and quilizumab, which should be assessed for their effects in patients with CIndU. 95 Our review is limited by the important but unavoidable fact that results could be potentially biased because we only identified published reports based on our specific MEDLINE search criteria, and failed uses of omalizumab are a lot less likely to have been reported in the literature. This is a relevant point but is very difficult to control for in systematic reviews of this nature. However, we did find 2 reports of omalizumab failure in patients with CIndUs and another report in which a patient with cold urticaria had to discontinue treatment because of inadequate symptom control and AEs. 45 This indicates that some, but probably not all, negative results have been published. Because in many patients CIndUs are not controlled by conventional H 1 -antihistamines, an unmet need exists for further controlled randomized trials in all patients with CIndUs, with special attention paid to those in which high-quality evidence in lacking. Additionally, further mechanistic studies are required to determine the pathophysiology of CIndUs.
